Choose Your Country or Region

Vedolizumab (anti-α4β7-integrin)

Synonyms: Entyvio

Catalog No.A2045 Purity:98%

Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.

Click to purchase the isotype control of Vedolizumab (anti-α4β7-integrin)

Purity & Quality Control

Batch: A204502 Purity: 98% Protein concentration: 5.72mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective Integrin Inhibitors

Name	Citation	Integrin
Cilengitide trifluoroacetate	66	+++
A-205804	5	++
Cyclo(RGDyK)	13	++
SB273005	25	++++
RGD (Arg-Gly-Asp) Peptides	✔
ATN-161	✔
Cyclo(-RGDfK) TFA	✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Vedolizumab (anti-α4β7-integrin) is a humanized IgG1 monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease.

In Vitro
In vitro	Vedolizumab (anti-α4β7-integrin) binds to a subset of human peripheral blood memory CD4⁺ T lymphocytes including gut-homing interleukin 17 T-helper lymphocytes at the highest level, also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; Vedolizumab binds to memory CD4⁺ T and B lymphocytes with subnanomolar potency with EC50 of 0.3-0.4 nM.^[1]
Cell Research:	PBMCs were resuspended in assay buffer for CD4 memory cell interleukin (IL) 17A intracellular staining. PBMCs were stimulated (or not stimulated, for the control samples) with 50 ng/ml phorbol 12-myristate 13-acetate and 1 µg/ml Ionomycin in the presence of 3 µM Monensin for 5 h at 37°C. After washing, cells were stained with fluorescent-labeled antibodies: vedolizumab, anti-α4 and anti-β7, anti-CD4, and anti-CD45RO, where applicable, at 4°C for 30 min. Cells were then washed with cold PBS and resuspended in fixation and permeabilization working solution staining buffer at 4°C for 30 min. After fixation and permeabilization, cells were washed with permeabilization buffer and blocked with 10% normal rat serum at 4°C for 10 min. After the blocking step, cells were stained with fluorochrome-conjugated anti_x0002_IL17A antibody at 4°C for 30 min. Finally, cells were washed with permeabilization buffer and analyzed.

In Vitro

In vitro

Vedolizumab (anti-α4β7-integrin) binds to a subset of human peripheral blood memory CD4⁺ T lymphocytes including gut-homing interleukin 17 T-helper lymphocytes at the highest level, also binds to eosinophils at high levels, and to naive T-helper lymphocytes, naive and memory cytotoxic T lymphocytes, B lymphocytes, natural killer cells, and basophils at lower levels; Vedolizumab binds to memory CD4⁺ T and B lymphocytes with subnanomolar potency with EC50 of 0.3-0.4 nM.^[1]

Cell Research:

PBMCs were resuspended in assay buffer for CD4 memory cell interleukin (IL) 17A intracellular staining. PBMCs were stimulated (or not stimulated, for the control samples) with 50 ng/ml phorbol 12-myristate 13-acetate and 1 µg/ml Ionomycin in the presence of 3 µM Monensin for 5 h at 37°C. After washing, cells were stained with fluorescent-labeled antibodies: vedolizumab, anti-α4 and anti-β7, anti-CD4, and anti-CD45RO, where applicable, at 4°C for 30 min. Cells were then washed with cold PBS and resuspended in fixation and permeabilization working solution staining buffer at 4°C for 30 min. After fixation and permeabilization, cells were washed with permeabilization buffer and blocked with 10% normal rat serum at 4°C for 10 min. After the blocking step, cells were stained with fluorochrome-conjugated anti_x0002_IL17A antibody at 4°C for 30 min. Finally, cells were washed with permeabilization buffer and analyzed.

References
[1] Soler D, et al. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75.

References

[1] Soler D, et al. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	943609-66-3
Molecular Weight	145.7 KD
Isotype	Human IgG1
Application	Vedolizumab (anti-α4β7-integrin)
Sterility	0.2 μM filtered
Formulation	PBS Buffer, PH 7.4
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.

Tags: buy Vedolizumab (anti-α4β7-integrin) | Vedolizumab (anti-α4β7-integrin) supplier | purchase Vedolizumab (anti-α4β7-integrin) | Vedolizumab (anti-α4β7-integrin) cost | Vedolizumab (anti-α4β7-integrin) manufacturer | order Vedolizumab (anti-α4β7-integrin) | Vedolizumab (anti-α4β7-integrin) distributor